1. At a Glance

Windlas Biotech is not your loud, ad-blasting pharma company. No celebrity doctors, no “for better digestion” jingles — just a quiet, consistent contract development and manufacturing (CDMO) machine for generics and complex generics. With 10 straight record quarters, the stock has climbed into the ₹900+ range, riding on steady 20% sales growth and a 31% jump in Q1 FY26 profit. Almost debt-free, high dividend payout, and working capital days slashed from 40 to 17 — this is the operational discipline most small caps can only dream of.

2. Introduction

If pharma was a Bollywood movie, Windlas would be the behind-the-scenes director — making the stars (Sun, Cipla, Dr. Reddy’s) look good without hogging the limelight.

They don’t own blockbuster brands; they make them for others. This B2B-only pharma player operates in the fastest-growing segment — contract manufacturing — where large players outsource product development and manufacturing to nimble, specialized players like Windlas.

While other pharma cos are busy battling USFDA warning letters, Windlas is churning out quarterly growth like clockwork. But the market has noticed — and is already valuing it at 30x earnings, which for a ₹2,000 Cr market cap smallcap is basically saying: “Don’t mess this up.”

3. Business Model (WTF Do They Even Do?)

Windlas Biotech operates across three verticals:

• CDMO (Core Business): Product discovery, development, licensing, and manufacturing — from basic generics to complex formulations.
• Trade Generics & OTC: Products sold under own labels in select geographies.
• Exports: Niche, small-batch orders for regulated and semi-regulated markets.

Roast: Think of them as a pharmaceutical kitchen — they cook your medicine to your recipe, pack it, and hand it over. The brand takes the credit; Windlas takes the cheque.

4. Financials Overview

TTM (FY25):

• Revenue: ₹795 Cr (20% YoY growth).
• EBITDA: ₹100 Cr (13% margin, stable for 3+ years).
• PAT: ₹65 Cr (up from ₹61 Cr in FY24).
• ROE: 12.8% | ROCE: 17%.
• Debt: ₹33 Cr — practically nil.
• Other Income: ₹19 Cr — nice bonus but not the growth driver.

P/E Recalc:
Q4 FY25 EPS = ₹7.79 → Annualised = ₹31.16 → Forward P/E ≈ 30.3x (in line with TTM).

Margins are remarkably steady, which in small-cap pharma is rarer than a government tender without delays.

5. Valuation (Fair Value RANGE only)

FV Range: ₹685 – ₹880

Disclaimer: This FV range is